Group's first public autism event receives a boost

A group of parents who came together to raise awareness of how autism affects individuals and families have had a boost for their first public event.
Stewart Clark, Right Worshipful Master, St Johns Coldstream 280, Masonic Lodge presents a cheque for £100 to Charlie and Barry Hamilton, representitives of the group Meeting of Minds (Autism Coldstream) along with Councillor John GreenwellStewart Clark, Right Worshipful Master, St Johns Coldstream 280, Masonic Lodge presents a cheque for £100 to Charlie and Barry Hamilton, representitives of the group Meeting of Minds (Autism Coldstream) along with Councillor John Greenwell
Stewart Clark, Right Worshipful Master, St Johns Coldstream 280, Masonic Lodge presents a cheque for £100 to Charlie and Barry Hamilton, representitives of the group Meeting of Minds (Autism Coldstream) along with Councillor John Greenwell

Retired doctor Alfred Wild read about the ‘Meeting of Minds’ event at Coldstream Primary School on Saturday, April 23, in the town’s local newsletter and contacted one of the organisers, Lauren Aitken, to offer his help.

Dr Wild’s brother Patrick lived with severe autism during the early part of the 20th century when there was no treatment and little understanding. After Patrick’s death the University of Edinburgh established a medical research centre of autism, Fragile X Syndrome and intellectual disabilities in his memory.

Hide Ad
Hide Ad

When he heard about the local event Dr Wild organised for a professor and a consultant from the centre to meet the families and children.

“It’s a fantastic opportunity for us,” said Lauren. “We will do a casual question and answer session within the school on the day. The centre is very keen to get on board with us and work with the group in the future.”

The Patrick Wild Centre brings together individuals from different areas of neuroscience research, to work with affected individuals and families to further understanding of autism and intellectual disabilities and accelerate development of new therapeutic options for people affected.